Sidley represented EDBI in its investment in Automera, a company developing an autophagy drug designed to target chimera small molecules (AUTACs), in its US$16M Series A financing round.
The round was co-led by U.S.-based Accelerator Life Sciences Partners (ALSP) and Temasek-backed ClavystBio, with participation of Xora Innovation and other investors.
The Sidley team was led by corporate partner Andrew Harper, and included private equity partner Parthiv Rishi, senior managing associate Eldon Chan, and associates Ryan Lim, and Yasmeen A. Sayyah.
